Status:
COMPLETED
Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate
Lead Sponsor:
Pfizer
Conditions:
Bacterial Infection
Eligibility:
MALE
18-55 years
Phase:
PHASE4
Brief Summary
The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other.
Eligibility Criteria
Inclusion
- Healthy male subjects between the ages of 18 and 55 years.
- Body Mass Index (BMI) of 18 to 30 kg/m2.
Exclusion
- Evidence or history of clinically significant abnormality.
- Any condition possibly affecting drug absorption.
- A positive urine drug screen.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00939562
Start Date
November 1 2008
End Date
December 1 2008
Last Update
December 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ahmedabad, Gujarat, India, 380 015